IDENTIFYING THERAPEUTIC AGENTS FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA Public Deposited

Downloadable Content

Download PDF
Last Modified
  • March 20, 2019
Creator
  • Cann, Marissa
    • Affiliation: School of Medicine, Department of Pharmacology
Abstract
  • Diffuse large B-cell lymphoma (DLBCL) can be categorized into two clinically relevant subtypes: activated B-cell (ABC) DLBCL and germinal center B-cell (GCB). Patients with ABC DLBCL have a worse prognosis, and are defined by chronic, overactive signaling through the B-cell receptor and NF-κB pathways. Signaling through the B-cell receptor is heavily dependent on the Src family kinases (SFKs), and NF-κB signaling is dependent on the proteasome. In Chapters 2 and 3, we examined the effects of the SFK inhibitor dasatinib in a panel of ABC and GCB DLBCL cell lines, with a focus on changes in the kinome (Chapter 2) or the proteasome (Chapter 3). In Chapter 2, we found that the ABC DLBCL cell lines are much more sensitive to dasatinib than the GCB DLBCL cell lines. However, both subtypes display inhibition of the SFKs in response to dasatinib treatment. Subsequent analyses revealed several cell cycle kinases to be inhibited by dasatinib treatment in the ABC DLBCL subtype, but not in the GCB DLBCL subtype. In Chapter 3, we found that treatment with dasatinib results in a decrease in the proteasome’s chymotrypsin-like (ChL), trypsin-like (TL), and caspase-like (CaL) activities in the ABC but not GCB DLBCL cell lines. Furthermore, it appears that association between the proteasome 20S core particle and 19S regulatory particle is disrupted in the ABC DLBCL cell lines after dasatinib treatment. In Chapter 4, we explored the utility of site-specific inhibitors of the proteasome’s TL and CaL activities in a variety of cancer cell lines. We found that the TL/ChL and CaL/ChL ratios of proteasome activity correlate with sensitivity to TL and CaL inhibitors, respectively. In addition, the two hematological malignancy cell lines studied are most sensitive to the site-specific inhibitors. Furthermore, the combination of the TL or CaL site-specific inhibitors with bortezomib or carfilzomib is synergistic in all cell lines examined. The studies presented in this thesis have important implications for the clinical use of dasatinib and site-specific proteasome inhibitors for the treatment of DLBCL, either alone or in combination with other agents. These inhibitors show promise and warrant further exploration.
Date of publication
Keyword
DOI
Resource type
Rights statement
  • In Copyright
Advisor
  • Sondek, John
  • Graves, Lee
  • Lawrence, David
  • Richards, Kristy
  • Johnson, Gary
Degree
  • Doctor of Philosophy
Degree granting institution
  • University of North Carolina at Chapel Hill Graduate School
Graduation year
  • 2017
Language
Parents:

This work has no parents.

Items